ArticleFrontiers in cellular and infection microbiology2026
Gut microbiota and serum metabolomics in children with human parainfluenza virus infection.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Based on gut microbiota and serum untargeted metabolomics analyses, this study investigated changes in gut microbiota structure and serum metabolic profiles in children infected with human parainfluenza virus (HPIV). By integrating multi-omics data, we aimed to explore interactions between gut dysbiosis and serum metabolic disorders, and their potential roles in HPIV pathogenesis, to provide preliminary evidence for microbiota--targeted and metabolic intervention strategies. Methods: Clinical data and laboratory results were collected from 230 hospitalized children (<14 years) with HPIV infection. Subsequently, 31 HPIV-infected children and 12 healthy controls were enrolled. Fecal samples were analyzed via 16S rRNA gene sequencing, and serum samples via liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based untargeted metabolomics, followed by integrated multi-omics analysis. Results: Children with severe HPIV infection had longer hospital stays and higher frequencies of wheezing, tachypnea, dyspnea, and vomiting. HPIV infection was associated with gut dysbiosis: opportunistic pathogens ( Conclusion: HPIV infection may be associated with gut microbiota dysbiosis and serum metabolic disturbances in children, potentially via the gut-lung axis, and these alterations may be involved in modulating pulmonary antiviral immune and inflammatory responses. This multi-omics study provides preliminary evidence for future research on prevention and treatment strategies targeting the gut microbiota or metabolic pathways in children with HPIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.